Chemerin as a Potential Marker of Resolution of Inflammation in COVID-19 Infection
Joanna Sulicka-Grodzicka,
Andrzej Surdacki,
Marcin Surmiak,
Marek Sanak,
Barbara Wizner,
Wojciech Sydor,
Monika Bociąga-Jasik,
Magdalena Strach,
Mariusz Korkosz,
Lubomir Skladany,
Ivica Grgurevic,
Kristian Podrug,
Michał Kukla
Affiliations
Joanna Sulicka-Grodzicka
Department of Rheumatology and Immunology, Jagiellonian University Medical College, 30-688 Cracow, Poland
Andrzej Surdacki
Institute of Cardiology, Jagiellonian University Medical College, 30-688 Cracow, Poland
Marcin Surmiak
Department of Internal Medicine, Jagiellonian University Medical College, 31-066 Cracow, Poland
Marek Sanak
Department of Internal Medicine, Jagiellonian University Medical College, 31-066 Cracow, Poland
Barbara Wizner
Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, 30-688 Cracow, Poland
Wojciech Sydor
Department of Rheumatology and Immunology, Jagiellonian University Medical College, 30-688 Cracow, Poland
Monika Bociąga-Jasik
Department of Infectious and Tropical Diseases, Jagiellonian University Medical College, 30-688 Cracow, Poland
Magdalena Strach
Department of Rheumatology and Immunology, Jagiellonian University Medical College, 30-688 Cracow, Poland
Mariusz Korkosz
Department of Rheumatology and Immunology, Jagiellonian University Medical College, 30-688 Cracow, Poland
Lubomir Skladany
Department of Internal Medicine and Hepatology, Gastroenterology and Liver Transplantation, F.D. Roosevelt University Hospital, 975-17 Banska Bystrica, Slovakia
Ivica Grgurevic
Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, 10000 Zagreb, Croatia
Kristian Podrug
Department of Gastroenterology and Hepatology, University Hospital Center, 21000 Split, Croatia
Michał Kukla
Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, 30-688 Cracow, Poland
Chemerin is one of the specialized pro-resolving mediators that participate in the early phase of inflammation and contribute to the initiation of the pro-resolving response. There is a paucity of data regarding the time course of chemerin during acute infections. We aimed to evaluate the sequence of inflammatory responses in the acute COVID-19 phase throughout onset and resolution of inflammation. We evaluated changes in selected biomarkers in COVID-19 survivors on the 7-day and 28-day follow up. Chemerin was lower in patients with baseline moderate/severe disease at day 7 compared with asymptomatic patients and individuals with mild illness (7265 [5526–9448] vs. 8730 [6888–11,058] pg/mL; p = 0.03). Only in patients with moderate/severe disease, but not in those with mild symptoms, were chemerin concentrations decreased one week after infection onset compared with baseline (7265 [5526–9448] vs. 8866 [6383–10,690] pg/mL; p p < 0.05). Resolution of inflammation in the group of moderate/severe SARS-CoV2 infection was associated with increasing serum concentrations of chemerin, contrary to pro-inflammatory cytokines and adipokines (pentraxin 3, TNFα, resistin, leptin). A similar pattern of angiopoietin-2 dynamics may suggest signs of enhanced vascularization as a consequence of acute SARS-CoV2 infection.
